Opendata, web and dolomites


Commercialization of a novel tool for designing personalized nOvel MelAnoma Therapies

Total Cost €


EC-Contrib. €






 COMbAT project word cloud

Explore the words cloud of the COMbAT project. It provides you a very rough idea of what is the project "COMbAT" about.

promise    enormous    therapies    holds    lack    regulatory    combination    young    population    economic    mutated    significantly    located    cancer    models    urgent    lethal    resistant    patient    caused    eliminated    types    preclinical    exact    realizing    trials    lower    toxicities    efficacy    systematic    incidence    serve    tumours    illustrates    clinical    burden    companies    manner    adverse    poc    skin    patent    psychological    costly    cells    treatments    industry    designed    suffering    diseases    business    start    expirations    innovative    pressures    candidates    unnecessary    pharmaceutical    genetic    metastasis    death    redefining    biotech    alarming    physiological    melanoma    treatment    undergo    propensity    backlash    drug    pigment    strategies    timelines    chemotherapy    patients    driver    mortality    creation    reactions    combat    designing    genes    landscape    screens    drugs    later    healthcare    combinatorial    genome    personalized    threats    mutations    believe    therapy    investments    person    tool    express    molecular    aggressive   

Project "COMbAT" data sheet

The following table provides information about the project.


Organization address
address: HERZL STREET 234
postcode: 7610001

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-PoC
 Funding Scheme ERC-POC
 Starting year 2015
 Duration (year-month-day) from 2015-10-01   to  2017-03-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WEIZMANN INSTITUTE OF SCIENCE IL (REHOVOT) coordinator 150˙000.00


 Project objective

Melanoma tumours develop in the pigment cells located in the skin. It is the most aggressive and treatment-resistant type of skin cancer as well as the leading cause of death among skin diseases. Moreover, melanoma’s alarming increase in incidence, especially in the young population, in combination with its propensity for lethal metastasis, illustrates an urgent need for new treatment strategies. In this PoC project, we propose developing an innovative tool, called COMbAT, for designing highly personalized therapies for melanoma patients. Each therapy will be based on existing, already designed drugs and will specifically target the driver mutations present in a patient’s melanoma genome.

COMbAT involves the use of novel unique preclinical models designed to express patient-derived mutated genes in melanoma cells in a physiological manner. These models will undergo systematic combinatorial drug screens aiming to target the exact driver mutations present in patients. Such personalized targeting of the patient’s melanoma genetic landscape is key to a significantly improved mortality. Specifically, COMbAT can serve as a unique preclinical tool in the delivery of healthcare, from redefining clinical trials to targeted treatments of melanoma patients to start and a wide range of other cancer types later. Importantly, as COMbAT will allow the increased use of specific targeting of molecular drug targets, it will help to significantly lower the patient’s economic and psychological burden caused by unnecessary chemotherapy. COMbAT also holds the promise of realizing value from enormous past investments in drug candidates that were eliminated due to person-specific toxicities or lack of efficacy. We thus believe that COMbAT will enable the creation of new business models for the pharmaceutical industry which is suffering from patent expirations, threats from biotech companies, regulatory pressures, costly drug development timelines, and backlash from adverse drug reactions.


year authors and title journal last update
List of publications.
2015 Rand Arafeh, Nouar Qutob, Rafi Emmanuel, Alona Keren-Paz, Jason Madore, Abdel Elkahloun, James S Wilmott, Jared J Gartner, Antonella Di Pizio, Sabina Winograd-Katz, Sivasish Sindiri, Ron Rotkopf, Ken Dutton-Regester, Peter Johansson, Antonia L Pritchard, Nicola Waddell, Victoria K Hill, Jimmy C Lin, Yael Hevroni, Steven A Rosenberg, Javed Khan, Shifra Ben-Dor, Masha Y Niv, Igor Ulitsky, Graham J Mann, Richard A Scolyer, Nicholas K Hayward, Yardena Samuels
Recurrent inactivating RASA2 mutations in melanoma
published pages: 1408-1410, ISSN: 1061-4036, DOI: 10.1038/ng.3427
Nature Genetics 47/12 2019-07-25

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COMBAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "COMBAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)


The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More  

VictPart (2019)

Righting Victim Participation in Transitional Justice

Read More